Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | LAP3 | P28838 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2590490 | 1.00 | LMNA (0.52) | LMNAMAPTSLC15A1TACR1GAA | |
| SCHEMBL5221398 | 1.00 | LMNA (0.52) | LMNAMAPTSLC15A1TACR1GAA | |
| SCHEMBL5115273 | 0.95 | MAPT (0.48) | LMNAMAPTSLC15A1TACR1GAA | |
| SCHEMBL12615481 | 0.95 | MAPT (0.48) | LMNAMAPTSLC15A1TACR1GAA | |
| SCHEMBL716533 | 0.95 | MAPT (0.48) | LMNAMAPTSLC15A1TACR1GAA | |
| SCHEMBL8813869 | 0.93 | P2RX7 (0.47) | LMNAMAPTSLC15A1TACR1GAA | |
| SCHEMBL6895557 | 0.93 | ALDH1A1 (0.50) | LMNAMAPTSLC15A1GAACA1 | |
| SCHEMBL8813866 | 0.93 | P2RX7 (0.47) | LMNAMAPTSLC15A1TACR1GAA | |
| SCHEMBL7302285 | 0.92 | LTA4H (0.56) | LMNAMAPTCA1CA2LTA4H | |
| SCHEMBL27403149 | 0.92 | MMP1 (0.46) | LMNAMAPTCA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110759967-A | Preparation method of carfilzomib | 雅本化学股份有限公司 | 2020-02-07 | — | — | CN | claimed |
| US-20220047698-A1 | SYNTHETIC INNATE IMMUNE RECEPTOR LIGANDS AND USES THEREOF | ALBERTA RES CHEMICALS INC (CA) | 2022-02-17 | — | — | US | disclosed |
| US-11185594-B2 | (Anti-HER2 antibody)-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-11-30 | — | — | US | disclosed |
| WO-2021095781-A1 | CARRIER FOR TRANSFER INTO IMMUNE CELLS AND USE THEREOF | 公立大学法人大阪 | 2021-05-20 | — | — | WO | disclosed |
| CN-110759967-A | Preparation method of carfilzomib | 雅本化学股份有限公司 | 2020-02-07 | — | — | CN | disclosed |
| CN-110759967-A | Preparation method of carfilzomib | 雅本化学股份有限公司 | 2020-02-07 | — | — | CN | disclosed |
| EP-3130608-B1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO CO LTD (JP) | 2019-09-04 | — | — | EP | disclosed |
| EP-3130608-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | Daiichi Sankyo Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
| US-8724296-B2 | Solid electrolytic capacitor and fabrication method thereof | SANYO ELECTRIC CO., LTD. (JP) | 2014-05-13 | — | — | US | disclosed |
| WO-1987004349-A1 | PEPTIDE ANALOGS | DELLARIA JOSEPH | 1987-07-30 | — | — | WO | disclosed |
| EP-0230266-A2 | Functionalized peptidyl aminodiols and -triols | ABBOTT LABORATORIES (US) | 1987-07-29 | — | — | EP | disclosed |
| EP-0212903-A2 | Polypeptide derivatives containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues | PFIZER INC. (US) | 1987-03-04 | — | — | EP | disclosed |
| US-4629736-A | HIGH FIBRINOLYTIC ACTION; WATER SOLUBILITY; ANTICOAGULANTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-12-16 | — | — | US | disclosed |
| EP-0155809-A2 | Renin inhibitors containing statine or derivatives thereof | PFIZER INC. (US) | 1985-09-25 | — | — | EP | disclosed |
| EP-0136879-A2 | Fatty acid derivatives and processes of producing them | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1985-04-10 | — | — | EP | disclosed |
| EP-0036713-B1 | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | UNIVERSITY OF MIAMI (US) | 1984-01-18 | — | — | EP | disclosed |
| EP-0009898-B1 | NOVEL ANTI-HYPERTENSIVE MERCAPTOACYLAMINO ACID DERIVATIVES, THEIR PREPARATION AND USE | UNIVERSITY OF MIAMI (US) | 1983-05-18 | — | — | EP | disclosed |
| EP-0036713-A2 | Angiotensin converting enzyme inhibitors | UNIVERSITY OF MIAMI (US) | 1981-09-30 | — | — | EP | disclosed |
| EP-0009898-A1 | Novel anti-hypertensive mercaptoacylamino acid derivatives, their preparation and use | UNIVERSITY OF MIAMI (US) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | ERBB2, EGFR, LANCL2 | LMNA 139/4885MAPT 836/4885SLC15A1 1082/4885 |
| US-11185594-B2 | (Anti-HER2 antibody)-drug conjugate | ERBB2, EGFR, LANCL2 | LMNA 139/4885MAPT 836/4885SLC15A1 1082/4885 |
| US-20220047698-A1 | SYNTHETIC INNATE IMMUNE RECEPTOR LIGANDS AND USES THEREOF | TLR3, TLR4, TLR9 | LMNA 2602/4885MAPT 2520/4885SLC15A1 2828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.